
Ric M Procyshyn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4477631/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Methamphetamine use: A comprehensive review of molecular, preclinical and clinical findings. Drug and Alcohol Dependence, 2013, 129, 167-179.	3.2	336
2	Clozapine Alone versus Clozapine and Risperidone with Refractory Schizophrenia. New England Journal of Medicine, 2006, 354, 472-482.	27.0	249
3	Cardiovascular side-effects of antipsychotic drugs: The role of the autonomic nervous system. , 2012, 135, 113-122.		125
4	Antipsychotic Polypharmacy: A Survey of Discharge Prescriptions from a Tertiary Care Psychiatric Institution. Canadian Journal of Psychiatry, 2001, 46, 334-339.	1.9	111
5	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	3.3	107
6	Persistent Antipsychotic Polypharmacy and Excessive Dosing in the Community Psychiatric Treatment Setting. Journal of Clinical Psychiatry, 2010, 71, 566-573.	2.2	104
7	Preclinical models of antipsychotic drug-induced metabolic side effects. Trends in Pharmacological Sciences, 2010, 31, 484-497.	8.7	97
8	The Hotel Study: Multimorbidity in a Community Sample Living in Marginal Housing. American Journal of Psychiatry, 2013, 170, 1413-1422.	7.2	82
9	Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment. Schizophrenia Research, 2008, 100, 252-260.	2.0	70
10	Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. Journal of Psychiatry and Neuroscience, 2007, 32, 331-8.	2.4	66
11	A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 945-954.	4.8	65
12	Antipsychotic Induced Dopamine Supersensitivity Psychosis: A Comprehensive Review. Current Neuropharmacology, 2016, 15, 174-183.	2.9	63
13	Community mental healthcare providers' attitudes and practices related to smoking cessation interventions for people living with severe mental illness. Patient Education and Counseling, 2009, 77, 289-295.	2.2	55
14	Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats. Journal of Psychiatry and Neuroscience, 2012, 37, 407-415.	2.4	52
15	Patterns of Antipsychotic Utilization in a Tertiary Care Psychiatric Institution. Pharmacopsychiatry, 2004, 37, 12-17.	3.3	49
16	Prevalence and Outcomes of Pharmaceutical Industry—Sponsored Clinical Trials Involving Clozapine, Risperidone, or Olanzapine. Canadian Journal of Psychiatry, 2004, 49, 601-606.	1.9	47
17	Clozapine-Induced Cardiovascular Side Effects and Autonomic Dysfunction: A Systematic Review. Frontiers in Neuroscience, 2018, 12, 203.	2.8	47
18	Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clinical Therapeutics, 1998, 20, 1203-1217.	2.5	46

#	Article	IF	CITATIONS
19	Risk of Gambling Disorder and Impulse Control Disorder With Aripiprazole, Pramipexole, and Ropinirole. Journal of Clinical Psychopharmacology, 2017, 37, 102-104.	1.4	46
20	Antipsychotic and Psychostimulant Drug Combination Therapy in Attention Deficit/Hyperactivity and Disruptive Behavior Disorders: A Systematic Review of Efficacy and Tolerability. Current Psychiatry Reports, 2013, 15, 355.	4.5	44
21	Medication Errors in Psychiatry. CNS Drugs, 2010, 24, 595-609.	5.9	42
22	Smoking cessation interventions among individuals in methadone maintenance: A brief review. Journal of Substance Abuse Treatment, 2010, 38, 191-199.	2.8	41
23	Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. International Clinical Psychopharmacology, 2014, 29, 125-137.	1.7	41
24	Concomitant clozapine reduces smoking in patients treated with risperidone. European Neuropsychopharmacology, 2002, 12, 77-80.	0.7	38
25	The Hotel Study—Clinical and Health Service Effectiveness in a Cohort of Homeless or Marginally Housed Persons. Canadian Journal of Psychiatry, 2017, 62, 482-492.	1.9	38
26	Gender-specific profiles of tobacco use among non-institutionalized people with serious mental illness. BMC Psychiatry, 2010, 10, 101.	2.6	36
27	Metabolic Side-Effects of the Novel Second-Generation Antipsychotic Drugs Asenapine and Iloperidone: A Comparison with Olanzapine. PLoS ONE, 2013, 8, e53459.	2.5	36
28	Mortality from treatable illnesses in marginally housed adults: a prospective cohort study. BMJ Open, 2015, 5, e008876.	1.9	34
29	Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver, Canada. PLoS Medicine, 2020, 17, e1003172.	8.4	32
30	A Focused Review of the Metabolic Side-Effects of Clozapine. Frontiers in Endocrinology, 2021, 12, 609240.	3.5	32
31	Plasma Protein and Lipoprotein Distribution of Clozapine. American Journal of Psychiatry, 2001, 158, 949-951.	7.2	30
32	Conceptual and Methodological Issues??in the Design of Clinical Trials??of Antipsychotics for the Treatment??of Schizophrenia. CNS Drugs, 2007, 21, 699-714.	5.9	28
33	Efficacy of longâ€acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and metaâ€analysis. Microbial Biotechnology, 2022, 16, 589-599.	1.7	27
34	White matter deficits assessed by diffusion tensor imaging and cognitive dysfunction in psychostimulant users with comorbid human immunodeficiency virus infection. BMC Research Notes, 2015, 8, 515.	1.4	26
35	Association between Serum Lipids and Antipsychotic Response in Schizophrenia. Current Neuropharmacology, 2019, 17, 852-860.	2.9	26
36	Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle. Journal of Clinical Psychopharmacology, 2015, 35, 447-449.	1.4	25

#	Article	IF	CITATIONS
37	Therapeutic Drug Levels of Second Generation Antipsychotics in Youth: A Systematic Review. Journal of Child and Adolescent Psychopharmacology, 2015, 25, 234-245.	1.3	24
38	Engineering Magnesium Selectivity in the Helix–Loop–Helix Calcium-Binding Motif. Archives of Biochemistry and Biophysics, 1995, 323, 115-119.	3.0	23
39	Clozapine's effects on body weight and resting metabolic rate: a case series. Schizophrenia Research, 2004, 66, 159-162.	2.0	23
40	Predictors of starting to smoke cigarettes in patients with first episode psychosis. Schizophrenia Research, 2009, 108, 258-264.	2.0	23
41	A comparison of psychotic symptoms in subjects with methamphetamine versus cocaine dependence. Psychopharmacology, 2017, 234, 1535-1547.	3.1	23
42	Antidiabetic-drug combination treatment for glucose intolerance in adult female rats treated acutely with olanzapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 48, 170-176.	4.8	22
43	Clinical and functional characteristics of young adults living in single room occupancy housing: preliminary findings from a 10-year longitudinal study. Canadian Journal of Public Health, 2018, 109, 204-214.	2.3	22
44	Cognitive decline and mortality in a community-based sample of homeless and precariously housed adults: 9-year prospective study. BJPsych Open, 2020, 6, e21.	0.7	22
45	Symptom changes in five dimensions of the Positive and Negative Syndrome Scale in refractory psychosis. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 673-682.	3.2	21
46	Housing First Improves Adherence to Antipsychotic Medication Among Formerly Homeless Adults With Schizophrenia: Results of a Randomized Controlled Trial. Schizophrenia Bulletin, 2017, 43, sbw136.	4.3	21
47	Association of Antidepressant Use With Drug-Related Extrapyramidal Symptoms. Journal of Clinical Psychopharmacology, 2018, 38, 349-356.	1.4	21
48	Olanzapine associated weight gain, Hyperglycemia and Neuroleptic Malignant Syndrome: case report. International Journal of Geriatric Psychiatry, 2002, 17, 326-328.	2.7	19
49	Clozapine-induced obsessive–compulsive symptoms: mechanisms and treatment. Journal of Psychiatry and Neuroscience, 2019, 44, 71-72.	2.4	19
50	Traumatic Brain Injury in a Community-Based Cohort of Homeless and Vulnerably Housed Individuals. Journal of Neurotrauma, 2017, 34, 3301-3310.	3.4	19
51	Clozapine-Associated Obsessive-Compulsive Symptoms and Their Management: A Systematic Review and Analysis of 107 Reported Cases. Psychotherapy and Psychosomatics, 2020, 89, 151-160.	8.8	19
52	A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy. Journal of Psychiatry and Neuroscience, 2009, 34, 433-42.	2.4	19
53	Antipsychotic polypharmacy increases metabolic dysregulation in female rats Experimental and Clinical Psychopharmacology, 2013, 21, 164-171.	1.8	18
54	An Evaluation of the Effects of the Novel Antipsychotic Drug Lurasidone on Glucose Tolerance and Insulin Resistance: A Comparison with Olanzapine. PLoS ONE, 2014, 9, e107116.	2.5	18

#	Article	IF	CITATIONS
55	Neurocognitive profiles of marginally housed persons with comorbid substance dependence, viral infection, and psychiatric illness. Journal of Clinical and Experimental Neuropsychology, 2014, 36, 1009-1022.	1.3	18
56	Prevalence and Patterns of Antipsychotic Use in Youth at the Time of Admission and Discharge From an Inpatient Psychiatric Facility. Journal of Clinical Psychopharmacology, 2014, 34, 17-22.	1.4	18
57	Effects of physical activity on the symptoms of Tourette syndrome: A systematic review. European Psychiatry, 2018, 48, 13-19.	0.2	18
58	Clozapine, elevated heart rate and QTc prolongation. Journal of Psychiatry and Neuroscience, 2018, 43, 71-72.	2.4	18
59	Differential Effects of Acute Treatment With Antipsychotic Drugs on Peripheral Catecholamines. Frontiers in Psychiatry, 2020, 11, 617428.	2.6	18
60	Clozapine administered once versus twice daily: Does it make a difference?. Medical Hypotheses, 2014, 82, 225-228.	1.5	17
61	A systematic review of the effects of CYP2D6 phenotypes on risperidone treatment in children and adolescents. Child and Adolescent Psychiatry and Mental Health, 2018, 12, 37.	2.5	17
62	Antipsychotic switching: results from a one-year prospective, observational study of patients with schizophrenia. Current Medical Research and Opinion, 2009, 25, 2121-2132.	1.9	16
63	Antipsychotic Medications: Linking Receptor Antagonism to Neuropsychological Functioning in First Episode Psychosis. Journal of the International Neuropsychological Society, 2012, 18, 717-727.	1.8	16
64	Risk of Extrapyramidal Adverse Events With Aripiprazole. Journal of Clinical Psychopharmacology, 2016, 36, 472-474.	1.4	16
65	Determination of Clozapine and its Metabolite, Norclozapine in Various Biological Matrices Using High-Performance Liquid Chromatography. Drug Development and Industrial Pharmacy, 2007, 33, 1158-1166.	2.0	15
66	Antipsychotic polypharmacy does not increase the risk for side effects. Schizophrenia Research, 2008, 98, 323-324.	2.0	15
67	Factors affecting severity of positive and negative symptoms of psychosis in a polysubstance using population with psychostimulant dependence. Psychiatry Research, 2016, 240, 336-342.	3.3	15
68	Antipsychotic-Associated Symptoms of Tourette Syndrome: A Systematic Review. CNS Drugs, 2018, 32, 917-938.	5.9	15
69	Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review. PLoS ONE, 2022, 17, e0267808.	2.5	15
70	The Pharmacokinetics of Second-Generation Long-Acting Injectable Antipsychotics: Limitations of Monograph Values. CNS Drugs, 2015, 29, 975-983.	5.9	14
71	Structural brain markers are differentially associated with neurocognitive profiles in socially marginalized people with multimorbid illness Neuropsychology, 2017, 31, 28-43.	1.3	13
72	Characterization of mental health in cannabis dispensary users, using structured clinical interviews and standardized assessment instruments. BMC Psychiatry, 2019, 19, 335.	2.6	13

#	Article	IF	CITATIONS
73	Efficacy and tolerability of aripiprazole versus D2 antagonists in the early course of schizophrenia: a systematic review and meta-analysis. NPJ Schizophrenia, 2021, 7, 29.	3.6	13
74	Pharmacoeconomics of Clozapine, Risperidone and Olanzapine. CNS Drugs, 2000, 13, 47-76.	5.9	12
75	Generic Clozapine. Pharmacoeconomics, 2003, 21, 1-11.	3.3	12
76	Characterization of white matter integrity deficits in cocaineâ€dependent individuals with substanceâ€induced psychosis compared with nonâ€psychotic cocaine users. Addiction Biology, 2017, 22, 873-881.	2.6	12
77	Cognitive Impairment in Marginally Housed Youth: Prevalence and Risk Factors. Frontiers in Public Health, 2019, 7, 270.	2.7	12
78	Elevated clozapine plasma concentration secondary to a urinary tract infection: proposed mechanisms. Journal of Psychiatry and Neuroscience, 2016, 41, E67-E68.	2.4	12
79	Do serum lipids predict response to clozapine treatment?. Journal of Psychiatry and Neuroscience, 2009, 34, 168.	2.4	12
80	A Comparison of Antipsychotic Drug-Defined Daily Doses Versus Chlorpromazine Equivalent Doses in Patients With or Without Extrapyramidal Motor Symptoms. Journal of Clinical Psychopharmacology, 2010, 30, 741-743.	1.4	11
81	Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness. Current Cardiovascular Risk Reports, 2013, 7, 283-287.	2.0	11
82	Cardiovascular effects of acute treatment with the antipsychotic drug olanzapine in rats. Vascular Pharmacology, 2014, 62, 143-149.	2.1	11
83	Cognition and Plasma Ratio of Clozapine to <i>N</i> -desmethylclozapine in Patients With Clozapine-Resistant Schizophrenia. American Journal of Psychiatry, 2015, 172, 1259-1259.	7.2	11
84	Reversal of Dopamine Supersensitivity as a Mechanism of Action of Clozapine. Psychotherapy and Psychosomatics, 2018, 87, 306-307.	8.8	11
85	Response trajectories to clozapine in a secondary analysis of pivotal trials support using treatment response to subtype schizophrenia. Canadian Journal of Psychiatry, 2015, 60, S19-25.	1.9	11
86	Personalized Risk Assessment of Drug-Related Harm Is Associated with Health Outcomes. PLoS ONE, 2013, 8, e79754.	2.5	10
87	Subcortical grey matter alterations in cocaine dependent individuals with substance-induced psychosis compared to non-psychotic cocaine users. Schizophrenia Research, 2016, 176, 158-163.	2.0	10
88	A comparison of regional brain volumes and white matter connectivity in subjects with stimulant induced psychosis versus schizophrenia. Psychopharmacology, 2019, 236, 3385-3399.	3.1	10
89	Effect of hypertriglyceridemia on the pharmacokinetics and blood–brain barrier penetration of clozapine and norclozapine following administration to rats. European Neuropsychopharmacology, 2010, 20, 545-552.	0.7	9
90	Effects of Exercise on Serum Triglycerides and Symptoms of Schizophrenia. Journal of Clinical Psychopharmacology, 2017, 37, 273-274.	1.4	9

#	Article	IF	CITATIONS
91	Cognitive profiles and associated structural brain networks in a multimorbid sample of marginalized adults. PLoS ONE, 2019, 14, e0218201.	2.5	9
92	Volumes of the Hippocampal Formation Differentiate Component Processes of Memory in a Community Sample of Homeless and Marginally Housed Persons. Archives of Clinical Neuropsychology, 2019, 34, 548-562.	0.5	9
93	The influence of dyslipidemia on the plasma protein and lipoprotein distribution of haloperidol. European Neuropsychopharmacology, 2003, 13, 33-37.	0.7	8
94	Competitive Displacement of Clozapine from Plasma Proteins in Normolipidemic and Hyperlipidemic Plasma Samples: Clinical Implications. Drug Development and Industrial Pharmacy, 2005, 31, 331-337.	2.0	8
95	Differential Effects of Alcohol Intoxication on S100B Levels Following Traumatic Brain Injury. Journal of Trauma, 2010, 68, 1065-1071.	2.3	8
96	Adverse events associated with switching antipsychotics. Journal of Psychiatry and Neuroscience, 2012, 37, E1-E2.	2.4	8
97	Proposing the Use of Partial AUC as an Adjunctive Measure in Establishing Bioequivalence Between Deltoid and Gluteal Administration of Long-Acting Injectable Antipsychotics. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 659-664.	1.6	8
98	Reduced cardiovascular fitness associated with exposure to clozapine in individuals with chronic schizophrenia. Psychiatry Research, 2018, 262, 28-33.	3.3	8
99	Antipsychotic prescribing patterns on admission to and at discharge from a tertiary care program for treatment-resistant psychosis. PLoS ONE, 2018, 13, e0199758.	2.5	8
100	A retrospective study of antipsychotic drug switching in a pediatric population. BMC Psychiatry, 2013, 13, 248.	2.6	7
101	Development of a cost-efficient novel method for rapid, concurrent genotyping of five common single nucleotide polymorphisms of the brain derived neurotrophic factor (BDNF) gene by tetra-primer amplification refractory mutation system. International Journal of Methods in Psychiatric Research, 2015, 24, 235-244.	2.1	7
102	Diffusion tensor imaging of neurocognitive profiles in a community cohort living in marginal housing. Brain and Behavior, 2019, 9, e01233.	2.2	7
103	Differential effects of cannabis exposure during early versus later adolescence on the expression of psychosis in homeless and precariously housed adults. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 106, 110084.	4.8	7
104	Breakthrough symptoms after switching long-acting injectable paliperidone palmitate from the gluteal to the deltoid site of administration. Journal of Psychiatry and Neuroscience, 2016, 41, E56-E57.	2.4	7
105	The Effects of Competitive Displacement on Haloperidol's Plasma Distribution in Normolipidemic and Hyperlipidemic Plasma. Drug Development and Industrial Pharmacy, 2005, 31, 901-905.	2.0	6
106	Corrected QT Intervals in Newly Admitted Geriatric Psychiatric Patients: An Examination of Risk Factors. Canadian Journal of Psychiatry, 2006, 51, 371-376.	1.9	6
107	A comparison of the metabolic side-effects of the second-generation antipsychotic drugs risperidone and paliperidone in animal models. PLoS ONE, 2021, 16, e0246211.	2.5	6
108	Management of sexual adverse effects induced by atypical antipsychotic medication. Journal of Psychiatry and Neuroscience, 2019, 44, 287-288.	2.4	6

#	Article	IF	CITATIONS
109	Valproic acid for seizure prophylaxis during clozapine therapy: Where's the evidence?. International Journal of Psychiatry in Clinical Practice, 1999, 3, 249-251.	2.4	5
110	Long-acting injectable risperidone in treatment refractory patients: A 14-week open-label pilot study. Schizophrenia Research, 2010, 123, 273-275.	2.0	5
111	Heart-rate response to alpha2-adrenergic receptor antagonism by antipsychotics. Clinical Autonomic Research, 2017, 27, 407-410.	2.5	5
112	Exercise-induced hippocampal neurogenesis: 5-HT3 receptor antagonism by antipsychotics as a potential limiting factor in Schizophrenia. Molecular Psychiatry, 2018, 23, 2252-2253.	7.9	5
113	Characterization of Bodily Pain and Use of Both Prescription and Non-Prescription Opioids in Tenants of Precarious Housing. Substance Use and Misuse, 2021, 56, 1951-1961.	1.4	5
114	Excessive Antipsychotic Dosing in a Canadian Outpatient Population. Psychiatric Services, 2011, 62, 682-683.	2.0	4
115	A Tetra-Primer Amplification Refractory System Technique for the Cost-Effective and Novel Genotyping of Eight Single-Nucleotide Polymorphisms of the Catechol-O-Methyltransferase Gene. Genetic Testing and Molecular Biomarkers, 2016, 20, 465-470.	0.7	4
116	Need for Bioequivalence Standards that Reflect the Clinical Importance of the Complex Pharmacokinetics of Paliperidone Palmitate Long-Acting Injectable Suspension. Journal of Pharmacy and Pharmaceutical Sciences, 2019, 22, 548-566.	2.1	4
117	Pain, opioid use, depressive symptoms, and mortality in adults living in precarious housing or homelessness: a longitudinal prospective study. Pain, 2022, 163, 2213-2223.	4.2	4
118	Theoretical Basis for Loxapine Augmentation in Risperidone Partial Responders. Clinical Drug Investigation, 2000, 19, 257-266.	2.2	3
119	Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment. Journal of Psychiatry and Neuroscience, 2014, 39, E32-E33.	2.4	3
120	Dimenhydrinate Use Disorder With Chronic Psychosis. Journal of Clinical Psychopharmacology, 2015, 35, 105-107.	1.4	3
121	Statin add-on therapy for schizophrenia: Is the effect the same for clozapine?. Psychiatry Research, 2018, 263, 289-290.	3.3	3
122	Dynamic networks of psychotic symptoms in adults living in precarious housing or homelessness. Psychological Medicine, 2021, , 1-11.	4.5	3
123	A ganglionic blocker and adrenoceptor ligands modify clozapine-induced insulin resistance. Psychoneuroendocrinology, 2021, 129, 105257.	2.7	3
124	Exercise and Worsening of Extrapyramidal Symptoms during Treatment with Long-Acting Injectable Antipsychotics. Pharmacy (Basel, Switzerland), 2021, 9, 123.	1.6	3
125	Antipsychotic Drug-Induced Increases in Peripheral Catecholamines are Associated With Glucose Intolerance. Frontiers in Pharmacology, 2022, 13, 765905.	3.5	3
126	Smoking, anticholinergics and schizophrenia. Schizophrenia Research, 2004, 67, 313-314.	2.0	2

8

#	Article	IF	CITATIONS
127	Risperidone long-acting injection in the treatment of schizophrenia spectrum illnesses: A retrospective chart review of 19 patients in the Vancouver Community Mental Health Organization (Vancouver, Canada). Current Therapeutic Research, 2007, 68, 409-420.	1.2	2
128	Exercise-associated extrapyramidal symptoms during treatment with long-acting injectable antipsychotic medications: A case report. Clinical Schizophrenia and Related Psychoses, 2017, , .	1.4	2
129	Risk of hair loss with different antidepressants. International Clinical Psychopharmacology, 2018, 33, 44-48.	1.7	1
130	Relationship between clozapine dose and severity of obsessive-compulsive symptoms. Medical Hypotheses, 2021, 148, 110506.	1.5	1
131	DR. Procyshyn replies. Clinical Therapeutics, 1999, 21, 925-930.	2.5	0
132	Response to the Letter to the Editor on "Paliperidone Palmitate Long-Acting Injectable Given Intramuscularly in the Deltoid Versus the Gluteal Muscle: Are They Therapeutically Equivalent?― Journal of Clinical Psychopharmacology, 2016, 36, 745-747.	1.4	0
133	How many clients with refractory psychosis are eligible for both cognitive-behaviour therapy and clozapine? A chart-review study. Cogent Psychology, 2019, 6, 1611208.	1.3	0
134	Decreased medial entorhinal cortical thickness in olanzapine exposed female rats is not ameliorated by exercise. Pharmacology Biochemistry and Behavior, 2020, 188, 172834.	2.9	0
135	Component Processes of Decision Making in a Community Sample of Precariously Housed Persons: Associations With Learning and Memory, and Health-Risk Behaviors. Frontiers in Psychology, 2021, 12, 571423.	2.1	0
136	Population pharmacokinetics and dosing of long-acting injectable antipsychotics. Journal of Psychiatry and Neuroscience, 2021, 46, E516-E517.	2.4	0
137	Withdrawal. Neuromethods, 2011, , 431-459.	0.3	Ο